A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

ConclusionErenumab did not alter the pharmacokinetics of the active components of an estrogen/progestin combination oral contraceptive. Thus, no change in contraceptive efficacy is expected with erenumab.Trial RegistrationClinicalTrials.gov NCT02792517.

http://link.springer.com/10.1007/s40263-019-00626-2

Source: CNS Drugs - April 7, 2019 Category: Neurology Source Type: research